Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714506 | 0.85 | ALDH1A1 (0.36) | MEN1KMT2APKMKDM4EGAA | |
| SCHEMBL10517816 | 0.72 | RIPK1 (0.42) | MEN1KMT2APKMKDM4EGAA | |
| SCHEMBL16196315 | 0.71 | CCNB2 (0.33) | GAA | |
| SCHEMBL18438840 | 0.68 | L3MBTL1 (0.36) | POLBMAPTL3MBTL1 | |
| SCHEMBL29009767 | 0.64 | FFAR1 (0.41) | TSHRALDH1A1MAPT | |
| SCHEMBL20897984 | 0.64 | LMNA (0.42) | MEN1KMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL8828511 | 0.63 | ROCK2 (0.47) | PKMTSHRPOLB | |
| SCHEMBL712142 | 0.63 | ALDH1A1 (0.62) | MEN1KMT2APKMKDM4EHPGD | |
| SCHEMBL30726837 | 0.63 | ALDH1A1 (0.62) | MEN1KMT2APKMKDM4EHPGD | |
| SCHEMBL30726838 | 0.63 | ALDH1A1 (0.62) | MEN1KMT2APKMKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2014-10-30 | — | — | US | disclosed |
| EP-2766344-A1 | EP1 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013037960-A1 | EP1 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | PTGER1, PTGER2, PTGIR | MEN1 2975/4885KMT2A 4002/4885PKM 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.